The new product is a ready-to-use, injectable bone matrix in paste form, consisting of 100 percent synthetic, non-particular, phase-pure hydroxylapatite. It can be used during orthopedic, trauma and neurosurgery procedures to fill and reconstruct bone defects or in conjunction with allograft and autograft as bone graft extender.
More Articles on Orthopedic Devices:
FDA Sends Warning Letters to California Orthopedic & Spine Device Companies
FDA Publishes Guidance for Pre-market Approvals
Wright Medical Group Names James Lightman Senior Vice President
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
